BACKGROUND: The Network for Pancreatic Organ Donors with Diabetes (nPOD) was established to recover and characterize pancreata and related organs from cadaveric organ donors with various risk levels for type 1 diabetes (T1D). These biospecimens are available to investigators for collaborative studies aimed at addressing questions related to T1D natural history and pathogenesis. RESEARCH DESIGN AND METHODS: Organ donors included T1D patients (new onset to long term), non-diabetic autoantibody-positive subjects, non-diabetic controls and individuals with disorders relevant to β-cell function. Pancreas recovery and transport met transplant-grade criteria. Additional samples recovered included serum, whole blood, spleen and pancreatic and non-pancreatic lymph nodes. Biospecimens were processed for cryopreserved cells, fixed paraffin and fresh frozen blocks and snap frozen samples. T1D autoantibodies, C-peptide levels and high-resolution HLA genotyping for risk alleles were also determined. RESULTS: Over 160 donors have been enrolled (ages of 1 day to >90 years). Standard operating procedures were established along with a quality management system. Donor demographics, laboratory assays and histopathological characterizations were shared through an open online informatics system. Biospecimens were distributed to more than 60 investigators. CONCLUSIONS: The nPOD programme provides access to high quality biospecimens without cost to investigators. Collaborations and open data sharing are emphasized to maximize research potential of each donor. On the basis of initial successes, the nPOD programme is expanding to recover additional organs relevant to T1D pathogenesis and complications from European countries (PanFin network).
BACKGROUND: The Network for Pancreatic Organ Donors with Diabetes (nPOD) was established to recover and characterize pancreata and related organs from cadaveric organ donors with various risk levels for type 1 diabetes (T1D). These biospecimens are available to investigators for collaborative studies aimed at addressing questions related to T1D natural history and pathogenesis. RESEARCH DESIGN AND METHODS: Organ donors included T1D patients (new onset to long term), non-diabetic autoantibody-positive subjects, non-diabetic controls and individuals with disorders relevant to β-cell function. Pancreas recovery and transport met transplant-grade criteria. Additional samples recovered included serum, whole blood, spleen and pancreatic and non-pancreatic lymph nodes. Biospecimens were processed for cryopreserved cells, fixed paraffin and fresh frozen blocks and snap frozen samples. T1D autoantibodies, C-peptide levels and high-resolution HLA genotyping for risk alleles were also determined. RESULTS: Over 160 donors have been enrolled (ages of 1 day to >90 years). Standard operating procedures were established along with a quality management system. Donor demographics, laboratory assays and histopathological characterizations were shared through an open online informatics system. Biospecimens were distributed to more than 60 investigators. CONCLUSIONS: The nPOD programme provides access to high quality biospecimens without cost to investigators. Collaborations and open data sharing are emphasized to maximize research potential of each donor. On the basis of initial successes, the nPOD programme is expanding to recover additional organs relevant to T1D pathogenesis and complications from European countries (PanFin network).
Authors: Janet Silverstein; Georgeanna Klingensmith; Kenneth Copeland; Leslie Plotnick; Francine Kaufman; Lori Laffel; Larry Deeb; Margaret Grey; Barbara Anderson; Lea Ann Holzmeister; Nathaniel Clark Journal: Diabetes Care Date: 2005-01 Impact factor: 19.112
Authors: Linda Yip; Leon Su; Deqiao Sheng; Pearl Chang; Mark Atkinson; Margaret Czesak; Paul R Albert; Ai-Ris Collier; Shannon J Turley; C Garrison Fathman; Rémi J Creusot Journal: Nat Immunol Date: 2009-08-09 Impact factor: 25.606
Authors: Peter In't Veld; Dirk Lievens; Joeri De Grijse; Zhidong Ling; Bart Van der Auwera; Miriam Pipeleers-Marichal; Frans Gorus; Daniel Pipeleers Journal: Diabetes Date: 2007-06-11 Impact factor: 9.461
Authors: R Gianani; M Campbell-Thompson; S A Sarkar; C Wasserfall; A Pugliese; J M Solis; S C Kent; B J Hering; E West; A Steck; S Bonner-Weir; M A Atkinson; K Coppieters; M von Herrath; G S Eisenbarth Journal: Diabetologia Date: 2010-01-09 Impact factor: 10.122
Authors: R Gianani; A Putnam; T Still; L Yu; D Miao; R G Gill; J Beilke; P Supon; A Valentine; A Iveson; S Dunn; G S Eisenbarth; J Hutton; P Gottlieb; A Wiseman Journal: J Clin Endocrinol Metab Date: 2006-02-14 Impact factor: 5.958
Authors: M Campbell-Thompson; L R Dixon; C Wasserfall; M Monroe; J M McGuigan; D Schatz; J M Crawford; M A Atkinson Journal: Diabetologia Date: 2008-11-11 Impact factor: 10.122
Authors: Stavros Diamantopoulos; Gloria Allende; Joseph M Ferreira; Gaetano Ciancio; George W Burke; Alberto Pugliese Journal: Diabetes Care Date: 2008-06-12 Impact factor: 19.112
Authors: Tihamer Orban; Jay M Sosenko; David Cuthbertson; Jeffrey P Krischer; Jay S Skyler; Richard Jackson; Liping Yu; Jerry P Palmer; Desmond Schatz; George Eisenbarth Journal: Diabetes Care Date: 2009-09-09 Impact factor: 17.152
Authors: M L Campbell-Thompson; M A Atkinson; A E Butler; N M Chapman; G Frisk; R Gianani; B N Giepmans; M G von Herrath; H Hyöty; T W Kay; O Korsgren; N G Morgan; A C Powers; A Pugliese; S J Richardson; P A Rowe; S Tracy; P A In't Veld Journal: Diabetologia Date: 2013-09-05 Impact factor: 10.122
Authors: Yi-Chun Chen; Richard E Mains; Betty A Eipper; Brad G Hoffman; Traci A Czyzyk; John E Pintar; C Bruce Verchere Journal: Diabetologia Date: 2020-01-27 Impact factor: 10.122